LeMaitre Vascular (NASDAQ:LMAT) Announces Earnings Results, Misses Expectations By $0.04 EPS

LeMaitre Vascular (NASDAQ:LMAT) released its quarterly earnings results on Wednesday. The medical instruments supplier reported $0.65 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.69 by ($0.04), FiscalAI reports. LeMaitre Vascular had a net margin of 25.02% and a return on equity of 15.63%. The business had revenue of $67.97 million for the quarter, compared to analysts’ expectations of $67.39 million. During the same period in the previous year, the company earned $0.75 EPS. LeMaitre Vascular’s revenue for the quarter was up 11.3% compared to the same quarter last year.

Here are the key takeaways from LeMaitre Vascular’s conference call:

• Q3 organic sales grew 12%, driven by 7% pricing and 5% unit growth, with gains across products and regions. LeMaitre reiterated 11% full-year organic growth guidance and expects adjusted EPS to rise 18% to $2.80.
• The B. Braun acquisition adds vascular grafts and other devices with $9.4 million in 2025 sales, but the commercial transition is expected to take 18–24 months. LeMaitre warned of potential customer losses during the transition and expects to record only about $150,000 of related revenue in Q4.
• RestoreFlow revenue grew 34%, including 65% growth in cardiac tissue, but quality-control processing constraints are limiting how much product the company can release and sell. Management said the bottleneck may persist for a while as it adds resources to address it.
• Full-year operating-margin guidance is 27%, with the outlook reduced by about $1.4 million, reflecting the FAS-TIP inventory reserve, faster sales-force and infrastructure investment, RestoreFlow transfer costs, and foreign-exchange pressure. Q3 operating expenses rose 18% year over year.

LeMaitre Vascular Stock Down 5.7%

LMAT traded down $4.97 during trading on Thursday, hitting $82.95. The stock had a trading volume of 409,844 shares, compared to its average volume of 279,302. The company has a market capitalization of $1.90 billion, a PE ratio of 29.07, a PEG ratio of 2.32 and a beta of 0.51. LeMaitre Vascular has a twelve month low of $78.22 and a twelve month high of $118.01. The company has a debt-to-equity ratio of 0.40, a quick ratio of 13.96 and a current ratio of 16.31. The stock has a 50 day simple moving average of $81.38 and a two-hundred day simple moving average of $94.16.

LeMaitre Vascular Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Investors of record on Thursday, November 19th will be given a dividend of $0.25 per share. The ex-dividend date of this dividend is Thursday, November 19th. This represents a $1.00 dividend on an annualized basis and a yield of 1.2%. LeMaitre Vascular’s dividend payout ratio is presently 35.09%.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on LMAT. Wells Fargo & Company lowered their price target on shares of LeMaitre Vascular from $94.00 to $86.00 and set an “equal weight” rating for the company in a report on Thursday. Seaport Research Partners set a $110.00 price objective on LeMaitre Vascular in a research report on Thursday. Weiss Ratings lowered LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, October 23rd. Citizens Jmp lowered their target price on shares of LeMaitre Vascular from $127.00 to $110.00 and set a “market outperform” rating for the company in a report on Thursday. Finally, Barrington Research cut LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 5th. Three equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, LeMaitre Vascular presently has a consensus rating of “Hold” and an average target price of $105.60.

Trending Headlines about LeMaitre Vascular

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: Third-quarter revenue was $67.97 million, above the $67.39 million consensus estimate and up 11.3% year over year. The company also declared a quarterly dividend of $0.25 per share. LeMaitre Q3 2026 Financial Results LeMaitre declares dividend
• Neutral Sentiment: Citizens JMP lowered its price target from $127 to $110 but maintained a “market outperform” rating, implying substantial upside from the cited share price. The lower target may temper optimism despite the continued positive rating. Citizens JMP stock recommendations
• Negative Sentiment: Adjusted earnings were $0.65 per share, below the $0.69 consensus estimate. The earnings miss appears to have outweighed the sales beat, and shares moved lower following the results. LeMaitre Vascular misses Q3 earnings estimates

About LeMaitre Vascular

LeMaitre Vascular, Inc is a medical device company focused on the treatment of peripheral vascular disease. The company develops, manufactures and markets products used primarily by vascular surgeons and other specialists in open vascular surgery procedures.

Its product portfolio includes biological and synthetic vascular grafts, carotid shunts, embolectomy and thrombectomy catheters, valvulotomes, vessel closure devices, vascular patches and surgical instruments. These products are designed to support procedures involving the arteries and veins, including the repair, reconstruction and treatment of diseased or obstructed blood vessels.

Founded in 1983 and headquartered in Burlington, Massachusetts, LeMaitre Vascular sells its products through a combination of direct sales personnel and distributors.